The invention relates to immunogenic products based on muteinamyloid ß(Aß) amino acid sequences, in particular to oligomers of Aß muteins, and to the use of said products in diagnosis, treatment and prevention of conditions such as amyloidoses, and for identifying agents capable of binding to said products.